C. R. Bradley

Iniparib plus Chemotherapy in Metastatic Triple-Negative Breast Cancer

Joyce O’Shaughnessy, Cynthia Osborne, John Pippen et al. · New England Journal of Medicine · 2011 · 802 citations

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

Joyce O’Shaughnessy, Cynthia R. Osborne, John Pippen et al. · Journal of Clinical Oncology · 2009 · 243 citations

Surgical Oncology, Breast Oncology, Tumoral Pathology +15

Colloid Formation During Waste Form Reaction: Implications for Nuclear Waste Disposal

J.K. Bates, J. P. Bradley, Anna S Teetsov et al. · Science · 1992 · 142 citations

Nuclear Waste Management, Engineering, Radioactive Contamination +20

Efficacy of BSI-201, a poly (ADP-ribose) polymerase-1 (PARP1) inhibitor, in combination with gemcitabine/carboplatin (G/C) in patients with metastatic triple-negative breast cancer (TNBC): Results of a randomized phase II trial

Joyce O’Shaughnessy, C. Osborne, John Pippen et al. · Journal of Clinical Oncology · 2009 · 94 citations

Breast Oncology, Medicine, Pharmacology +11

Evidence for the efficacy of Iniparib, a PARP-1 inhibitor, in BRCA2-associated pancreatic cancer.

David R. Fogelman, Robert A. Wolff, Scott Kopetz et al. · PubMed · 2011 · 93 citations

Brca2 Mutation, Oncology, Parp Inhibition +13